FOR IMMEDIATE RELEASE

OncoQuest Announces Presentation of Translational Immunology Data from Phase 2 Clinical Study Examining Oregovomab in Combination with Chemotherapy in Front Line Ovarian Cancer at the International Meeting of European Society of Gynaecological Oncology (ESGO) 2017

EDMONTON, ALBERTA, November 7, 2017 OncoQuest Inc. ("OncoQuest"), a biopharmaceutical company developing immunotherapeutic antibodies for the treatment of ovarian, pancreatic and other cancer, today announced that it will be presenting a poster titled "Translational Correlates of Indirect Antibody Immunization Using Scheduled Combination Therapy with Carboplatin Paclitaxel Plus Oregovomab: A Randomized Study" at the International Meeting of European Society of Gynaecological Oncology (ESGO) 2017, to be held November 4 - 7 in Vienna, Austria.

The findings presented were drawn from the 81 patients in the trial from the Italian investigative centers and demonstrated that there was a higher proportion of patients with treatment-emergent increases in CA125-specific IFN-g-producing CD8+ T cells in the arm which combined oregovomab with carboplatin-paclitaxel chemotherapy than in the carboplatin-paclitaxel arm alone. This increase was associated with significantly better relapse free survival (RFS).

"The immunology translational data further supports our belief that combination immunotherapy using oregovomab can induce an antigen specific T-cell response, which can translate to clinical benefits as observed from our recently released interim clinical data from the same study" stated Dr. Madiyalakan, CEO of OncoQuest.

OncoQuest is also conducting two other clinical studies in the recurrent ovarian cancer setting by combining oregovomab with nivolumab, a checkpoint inhibitor and Hiltonol®, an investigational TLR3 agonist, respectively. OncoQuest also recently announced that it entered into a collaboration agreement with Tesaro to combine ZEJULA®, a PARP inhibitor with oregovomab, also in the recurrent setting.

About Oregovomab

Oregovomab is OncoQuest's high affinity monoclonal antibody (Mab B43.13) that is designed to bind to the tumor associated antigen CA125 (also designated MUC16) and initiate a cascade of immune responses against this glycoprotein. CA125 is expressed in epithelial ovarian cancer on the tumor surface, but is also shed into the circulation. OncoQuest believes that carboplatin paclitaxel based chemotherapy used in front line treatment in a precisely scheduled combination with oregovomab can improve outcomes relative to chemotherapy alone and is currently exploring the role of select immune modulators and checkpoint inhibition to assess oregovomab's application in advanced disease settings.

About OncoQuest

OncoQuest is a subsidiary of Quest PharmaTech Inc. (TSXV-QPT) ("Quest"), and is a private biopharmaceutical company focused on the development and commercialization of immunotherapies for cancer. OncoQuest's technology platform includes a panel of tumor antigen specific monoclonal immunoglobulins including CA125, MUC1, PSA and Her2/neu; and the application of combinatorial immunotherapy to enhance tumor specific immunity and clinical outcome. OncoQuest's lead product is oregovomab for the treatment of ovarian cancer that is currently undergoing multiple Phase 2 clinical trials. OncoQuest's MUC1 program has already undergone a Phase 1 clinical trial in breast cancer patients, and its development is being led by OncoVent Co. Ltd., OncoQuest's Chinese joint venture partner that has licensed the rights of the immunotherapy technologies in the territory of Greater China. OncoQuest's next-generation products are based on immunoglobulin E licensed from UCLA, Stanford University and Advanced Immune Therapeutics, Inc. These antigen-specific monoclonal IgE antibodies are currently in preclinical development.

Forward Looking Statements

This press release includes forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions. These statements are based on management's expectations and assumptions as of the date of this press release and are subject to a number of risks and uncertainties, many of which are difficult to predict that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. The information in this release is provided only as of the date of this release and the company undertakes no obligation to update any forward-looking statements contained in this release based on new information, future events, or otherwise, except as required by law.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For further information: Hany S. Awadalla, Senior Vice President and Chief Financial Officer, OncoQuest Inc.
Tel: (917) 745-7940, Email: hawadalla@oncoquestinc.com, Internet: www.oncoquestinc.com